Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
24 hour
acute respiratory distress
Administered
administration
Aerogen
Aerogen Solo®
Aerosols
age
airway
alveolar
alveolar injury
anticipated
ARDS
backbone
Berlin criteria
blinded
blocker
Breastfeeding
carrier
cell-free DNA
citrullinated histones
clearance
cleave
Clinical practice
clinical trial
comparator
Compound
computer-generated
consecutive patient
control arm
coronavirus 2
coronavirus disease
COVID-19
COVID-19 patients
criteria
damage-associated molecular pattern
DAMP
DAMPs
diagnosed with COVID-19
dissemination
distal
Dornase alfa
dose
double-stranded
DSMB
Efficacy
element
eliminated
enteral nutrition
Extracellular
extracellular DNA
fibrosis
glycemic control
hospital
Hospitalized
hospitals
hyperinflammation
hypersensitivity
ICU
Inclusion
inclusion criteria
induce
Inflammation
intensive care
interim analysis
Intervention
Ireland
less
looser
lung
lung damage
Lungs
management
mechanical ventilation
mechanically ventilated patient
monitoring board
myeloperoxidase
NET
NETs
neutrophil
Neutrophil extracellular trap
Neutrophil extracellular traps
number
objective
Occurrence
Open-label
outcome
PaO
Paris
participant
Patient
patients
PEEP
performed
Pneumocytes
Primary outcome
progression
Prone position
Protective
protocol
randomisation
randomised
randomised controlled trial
Randomized
receive
recruit
recruitment
reduce
reducing
Registered
respiratory
Roche
Rothschild
Sample size
SARS-CoV-2
secretion
Sedation
Severe COVID-19 pneumonia
severe pneumonia
severity
statistical analysis
status
study group
Study protocol
Switzerland
syndrome
to define
Toxicity
tracheal
Treatment
Trial
usual care
Ventilation
vibrating mesh nebulizer
Volume
website
[DOI] 10.1186/s13063-020-04488-8 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04488-8 PMC 바로가기 [Article Type] Letter